Anupam Rama
Stock Analyst at JP Morgan
(4.50)
# 288
Out of 5,182 analysts
313
Total ratings
50.97%
Success rate
21.66%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $37 → $41 | $40.41 | +1.46% | 20 | Apr 1, 2026 | |
| MAZE Maze Therapeutics | Maintains: Overweight | $52 → $58 | $28.71 | +102.02% | 3 | Mar 31, 2026 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $44 → $41 | $30.44 | +34.69% | 5 | Mar 25, 2026 | |
| SLDB Solid Biosciences | Maintains: Overweight | $11 → $12 | $7.49 | +60.21% | 10 | Mar 25, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $39 → $32 | $20.41 | +56.79% | 14 | Mar 18, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $55 → $58 | $15.06 | +285.13% | 7 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Overweight | $24 → $25 | $17.81 | +40.37% | 2 | Mar 18, 2026 | |
| CTMX CytomX Therapeutics | Upgrades: Overweight | $7 → $12 | $4.56 | +163.16% | 4 | Mar 16, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $176 → $177 | $131.60 | +34.50% | 22 | Mar 12, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $120 → $74 | $22.45 | +229.62% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $27 → $22 | $21.45 | +0.23% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $94 | $73.15 | +28.50% | 13 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $45 | $25.15 | +78.93% | 12 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $10.72 | +198.51% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $96 | $40.86 | +134.95% | 12 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $67 | $35.21 | +90.29% | 9 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $40 | $18.05 | +121.61% | 2 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $147 → $145 | $105.43 | +37.53% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $7.70 | -22.08% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $20 | $8.89 | +124.97% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.14 | +29.38% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.44 | +31.58% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $40.63 | -40.93% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $32.74 | +141.30% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $8.41 | +30.80% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.47 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $23.23 | +3.31% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $57.68 | +38.70% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $48.82 | -18.07% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.90 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.42 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.50 | +136.36% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $4.99 | +4,910.02% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.18 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $66.73 | -13.08% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $16.02 | -25.09% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $9.06 | +308.39% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $103.78 | -47.00% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.20 | +272.55% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $35.20 | +53.41% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.13 | +34,409.20% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.84 | +43.31% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $318.85 | -57.03% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.34 | +553.95% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.92 | +3,159.45% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $67.77 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.54 | - | 2 | Jul 21, 2017 |
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $37 → $41
Current: $40.41
Upside: +1.46%
Maze Therapeutics
Mar 31, 2026
Maintains: Overweight
Price Target: $52 → $58
Current: $28.71
Upside: +102.02%
Travere Therapeutics
Mar 25, 2026
Maintains: Overweight
Price Target: $44 → $41
Current: $30.44
Upside: +34.69%
Solid Biosciences
Mar 25, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $7.49
Upside: +60.21%
Zai Lab
Mar 18, 2026
Maintains: Overweight
Price Target: $39 → $32
Current: $20.41
Upside: +56.79%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Overweight
Price Target: $55 → $58
Current: $15.06
Upside: +285.13%
Erasca
Mar 18, 2026
Maintains: Overweight
Price Target: $24 → $25
Current: $17.81
Upside: +40.37%
CytomX Therapeutics
Mar 16, 2026
Upgrades: Overweight
Price Target: $7 → $12
Current: $4.56
Upside: +163.16%
Neurocrine Biosciences
Mar 12, 2026
Maintains: Overweight
Price Target: $176 → $177
Current: $131.60
Upside: +34.50%
Ultragenyx Pharmaceutical
Mar 12, 2026
Maintains: Overweight
Price Target: $120 → $74
Current: $22.45
Upside: +229.62%
Mar 11, 2026
Downgrades: Neutral
Price Target: $27 → $22
Current: $21.45
Upside: +0.23%
Mar 10, 2026
Maintains: Overweight
Price Target: $89 → $94
Current: $73.15
Upside: +28.50%
Mar 9, 2026
Maintains: Overweight
Price Target: $33 → $45
Current: $25.15
Upside: +78.93%
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $10.72
Upside: +198.51%
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $40.86
Upside: +134.95%
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $35.21
Upside: +90.29%
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $18.05
Upside: +121.61%
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $105.43
Upside: +37.53%
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $7.70
Upside: -22.08%
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $8.89
Upside: +124.97%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.14
Upside: +29.38%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.44
Upside: +31.58%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $40.63
Upside: -40.93%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $32.74
Upside: +141.30%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $8.41
Upside: +30.80%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.47
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $23.23
Upside: +3.31%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $57.68
Upside: +38.70%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $48.82
Upside: -18.07%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.90
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.42
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.50
Upside: +136.36%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $4.99
Upside: +4,910.02%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.18
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $66.73
Upside: -13.08%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $16.02
Upside: -25.09%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $9.06
Upside: +308.39%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $103.78
Upside: -47.00%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.20
Upside: +272.55%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $35.20
Upside: +53.41%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.13
Upside: +34,409.20%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.84
Upside: +43.31%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $318.85
Upside: -57.03%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.34
Upside: +553.95%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.92
Upside: +3,159.45%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $67.77
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.54
Upside: -